UBS Reduces PT on Owens & Minor, Inc. (OMI) from $13 to $7 Following Weaker Q2 2025 Results

With a price-to-earnings multiple under 15x and its relative strength index below 40, Owens & Minor, Inc. (NYSE:OMI) secures a spot on our list of the 13 Oversold Value Stocks to Invest in Now.

On August 13, 2025, UBS reduced its price target on Owens & Minor, Inc. (NYSE:OMI) from $13 to $7, keeping a ‘Buy’ rating. The price revision follows the company’s weaker Q2 results and a cautious outlook.

Furthermore, the downgrade is associated with the company’s short-term dissynergies from the Patient & Healthcare Services sale and the loss of Kaiser. As a result of these dissynergies, the investment firm expects dampened EBIT for Owens & Minor, Inc. (NYSE:OMI) in 2026.

Yet UBS expects $700 million in potential proceeds from the P&HS sale, which could help Owens & Minor, Inc. (NYSE:OMI) reduce its debt. On the positive side, the analyst highlighted growth catalysts, such as diabetes recovery, sleep therapy momentum, improved capital efficiency, and reduced exposure to struggling hospital purchasing. UBS expects the company to return to profitability in 2025, projecting FY2025 EPS of $1.24.

Through its Products & Healthcare Services and Patient Direct segments, Owens & Minor, Inc. (NYSE:OMI) delivers healthcare solutions globally. It is one of the oversold stocks.

While we acknowledge the potential of OMI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 11 Best Gold Penny Stocks to Buy According to Hedge Funds and 11 Best Rebound Stocks to Buy According to Hedge Funds.

Disclosure: None.